Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Chagas disease 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
2 Chagas disease 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
3 Chagas disease 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
4 Epstein-Barr virus infection 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
5 Epstein-Barr virus infection 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
6 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
7 Hematopoietic cell lineage 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
8 Hematopoietic cell lineage 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
9 Hematopoietic cell lineage 💬
 [2] CD3E, MS4A1 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
10 Human immunodeficiency virus 1 infection 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
11 Human immunodeficiency virus 1 infection 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
12 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
13 Human T-cell leukemia virus 1 infection 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
14 Human T-cell leukemia virus 1 infection 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
15 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
16 Measles 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
17 Measles 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
18 Measles 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
19 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
20 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
21 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
22 Primary immunodeficiency 💬
 [2] CD3D, CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
23 Primary immunodeficiency 💬
 [2] CD3D, CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
24 Primary immunodeficiency 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
25 T cell receptor signaling pathway 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
26 T cell receptor signaling pathway 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
27 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
28 Th1 and Th2 cell differentiation 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
29 Th1 and Th2 cell differentiation 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
30 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
31 Th17 cell differentiation 💬
 [3] CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
32 Th17 cell differentiation 💬
 [3] CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
33 Th17 cell differentiation 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬

Back to top